Save time and get answers to complex questions with AI chat
Abbvie humira patent cliff navigation success?Dabrafenib patent expiration date novartis gsk composition matter?When will a generic version of xiaflex be available?What's the recommended schedule for lurbinectedin side effect checks?Xiaflex market launch year?
See the DrugPatentWatch profile for Onivyde
Information on discount programs for Onivyde is not readily available in the provided context.
Onivyde (nal-IRI) is a liposomal encapsulation of irinotecan, used in combination with fluorouracil and leucovorin to treat patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based chemotherapy [1].
Onivyde is a topoisomerase I inhibitor. The liposomal encapsulation aims to alter the distribution and delivery of irinotecan. By encapsulating irinotecan in liposomes, the drug is intended to accumulate in tumors and release its active component over time [1].
Ipsen Biopharmaceuticals, Inc. is the manufacturer of Onivyde [1].
The U.S. Food and Drug Administration (FDA) approved Onivyde for its indicated use in October 2015 [1].
Other Questions About Onivyde :